Counseling plus Buprenorphine–Naloxone Maintenance Therapy for Opioid Dependence
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The optimal level of counseling and frequency of attendance for medication distribution has not been established for the primary care, office-based buprenorphine-naloxone treatment of opioid dependence. METHODS: We conducted a 24-week randomized, controlled clinical trial with 166 patients assigned to one of three treatments: standard medical management and either once-weekly or thrice-weekly medication dispensing or enhanced medical management and thrice-weekly medication dispensing. Standard medical management was brief, manual-guided, medically focused counseling; enhanced management was similar, but each session was extended. The primary outcomes were the self-reported frequency of illicit opioid use, the percentage of opioid-negative urine specimens, and the maximum number of consecutive weeks of abstinence from illicit opioids. RESULTS: The three treatments had similar efficacies with respect to the mean percentage of opioid-negative urine specimens (standard medical management and once-weekly medication dispensing, 44 percent; standard medical management and thrice-weekly medication dispensing, 40 percent; and enhanced medical management and thrice-weekly medication dispensing, 40 percent; P=0.82) and the maximum number of consecutive weeks during which patients were abstinent from illicit opioids. All three treatments were associated with significant reductions from baseline in the frequency of illicit opioid use, but there were no significant differences among the treatments. The proportion of patients remaining in the study at 24 weeks did not differ significantly among the patients receiving standard medical management and once-weekly medication dispensing (48 percent) or thrice-weekly medication dispensing (43 percent) or enhanced medical management and thrice-weekly medication dispensing (39 percent) (P=0.64). Adherence to buprenorphine-naloxone treatment varied; increased adherence was associated with improved treatment outcomes. CONCLUSIONS: Among patients receiving buprenorphine-naloxone in primary care for opioid dependence, the efficacy of brief weekly counseling and once-weekly medication dispensing did not differ significantly from that of extended weekly counseling and thrice-weekly dispensing. Strategies to improve buprenorphine-naloxone adherence are needed. (ClinicalTrials.gov number, NCT00023283 [ClinicalTrials.gov].).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Whereas treatment outcomes did not vary significantly by treatment condition,5 patient satisfaction did (F[2, 139] = 3.16, P = .03).”
From Patient Satisfaction with Primary Care Office-Based Buprenorphine/Naloxone Treatment (2007) · cites this paper as [5]
In the citing paper
“This paucity of research is particularly noteworthy given the increasing availability and demonstrated efficacy of office-based buprenorphine/naloxone treatment.5–7”
From Patient Satisfaction with Primary Care Office-Based Buprenorphine/Naloxone Treatment (2007) · cites this paper as [5]
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. (2013) · Encyclopedia of Social Work · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,519
The Effects of Psychosocial Services in Substance Abuse Treatment
McLellan, A. T. (1993) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1993.03500150065028 · Cited by 869
Clinical pharmacology of buprenorphine: Ceiling effects at high doses
Walsh, S. L., Preston, K. L., Stitzer, M. L., Cone, E. J., & Bigelow, G. E. (1994) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1994.71 · Cited by 773
A Comparison of Levomethadyl Acetate, Buprenorphine, and Methadone for Opioid Dependence
Johnson, R. E., Chutuape, M. A., Strain, E. C., Walsh, S. L., Stitzer, M. L., & Bigelow, G. E. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011023431802 · Cited by 623
Fudala, P. J., Bridge, T. P., Herbert, S., Williford, W. O., Chiang, C. N., Jones, K., Collins, J., Raisch, D., Casadonte, P., Goldsmith, R. J., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022164 · Cited by 577
Crits-Christoph, P. (1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.6.493 · Cited by 496
Ensuring balanced distribution of prognostic factors in treatment outcome research.
Stout, R. L., Wirtz, P. W., Carbonari, J. P., & Del Boca, F. K. (1994) · Journal of Studies on Alcohol, Supplement · doi:10.15288/jsas.1994.s12.70 · Cited by 461
Sees, K. L., Delucchi, K. L., Masson, C., Rosen, A., Clark, H. W., Robillard, H., Banys, P., & Hall, S. M. (2000) · JAMA · doi:10.1001/jama.283.10.1303 · Cited by 415
Buprenorphine maintenance treatment of opiate dependence: a multicenter, randomized clinical trial
Ling, W., Charuvastra, C., Collins, J. F., Batki, S., Brown, L. S., Kintaudi, P., Wesson, D. R., Mcnicholas, L., Tusel, D. J., Malkerneker, U., et al. (1998) · Addiction · doi:10.1046/j.1360-0443.1998.9344753.x · Cited by 402
Carroll, K. (2000) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(99)00049-6 · Cited by 386
Research works printed but not linked: 1
- Amato L, 2004, Cochrane Database Syst Rev, 4, CD005031
Cited by
Items 301–351 of 351
Opioids: Heroin and Prescription Drugs
White, J. M. (2010) · Springer eBooks · doi:10.1007/978-1-4419-0338-9_51 · Cited by 1
Video-telecare collaborative pain management during COVID-19: a single-arm feasibility study
Rogers, D. G., Frank, J. W., Wesolowicz, D. M., Nolan, C., Schroeder, A., Falker, C. G., Abelleira, A., Moore, B. A., Becker, W. C., & Edmond, S. N. (2023) · BMC Family Practice · doi:10.1186/s12875-023-02052-2 · Cited by 2
Self-citationWare, O. D., Novak, M. D., & Toegel, F. (2024) · Journal of Drug Issues · doi:10.1177/00220426241238957 · Cited by 2
“However, it is also worth noting that among individuals with lower complexity OUD, evidenced-based medications alone, absent behavioral interventions, have provided effective treatment (Fiellin et al., 2006).”
A Source Control Model for Treatment-Resistant Substance Use Disorder
Dernbach, M. R., Drexler, K. P. G., McCord, E., & Carpenter, J. E. (2024) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000001344 · Cited by 1
Shared Medical Appointments Role in the Opioid Epidemic Era: A Tool for Integration of Care
Daum, A. M., Rivera, H. C., & Nykiel, S. (2017) · Journal of Addiction Research & Therapy · doi:10.4172/2155-6105.1000328 · Cited by 1
“Other significant limitations to providers being willing to treat OUD patients was the fear of patient neediness, high cost, and time constraints-namely challenges associated with the frequency of needed visits, especially early in the treatment [38-45].”
BackgroundBuprenorphine/naloxone maintenance for “poppy husk” dependence: A retrospective study
Tikka, S. K., Singh, L. K., Spoorthy, M. S., Purushotham, A., & Suchandra, K. H. H. (2019) · Asia-Pacific Psychiatry · doi:10.1111/appy.12358 · Cited by 1
“However, among those who used prescription and injection opioid use, level of counseling has not been found to be significantly associated with retention (Fiellin et al., 2006).”
BackgroundHimelhoch, S. S., Currens, M., Benford, J., & Weintraub, E. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.98462 · Cited by 1
Niebergall, H. (2007) · Springer eBooks · doi:10.1007/978-3-540-33734-8_2 · Cited by 2
Is Buprenorphine-Naloxone Ready for Prime Time in the Treatment of Opioid Addiction in Managed Care?
Curtiss, F. R. (2008) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2008.14.2.195 · Cited by 1
Choi, D., Karpyak, V. M., Frye, M. A., Hall‐Flavin, D. K., & Mrazek, D. A. (2009) · Elsevier eBooks · doi:10.1016/b978-1-4160-3291-5.50059-7 · Cited by 2
Substance Abuse: Opioid‐Related Disorders
WOODY, G. E., & Fudala, P. J. (2015) · Wiley eBooks · doi:10.1002/9781118753378.ch78
The impact of regulatory changes on the providers of treatment for opioid dependence
Fisher, P. A. (2011) · Human Biology
Methode und Qualität der Adhärenzmessung in randomisiert kontrollierten Studien: Systematic Review
Schönborn, P. (2009) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-761 · Cited by 1
Substance Use Treatment in the Era of New HIV Prevention Technologies
Metzger, D. S. (2013) · Springer eBooks · doi:10.1007/978-1-4614-8845-3_8
Onderhoudstherapie bij opiaatafhankelijkheid: buprenorfine, naloxon en consult
Smink, B. E. (2007) · Medisch-Farmaceutische Mededelingen · doi:10.1007/bf03058914
Mise à jour sur l’utilisation clinique de la buprénorphine: pour les troubles reliés aux opioïdes
Ducharme, S., Fraser, R., & Gill, K. (2012) · PubMed Central
Bart, G. B. (2013) · University of Minnesota Digital Conservancy (University of Minnesota) · Cited by 1
Opiates and Prescription Drugs
Renner, J. A., & Suzuki, J. (2010) · Springer eBooks · doi:10.1007/978-1-4419-0338-9_21 · Cited by 1
“4 days/week during a 6-month buprenorphine maintenance trial; 50–57% of the participants had at least one cocaine-positive urine test during the 6-month trial [41].”
BackgroundBuprenorphine-Naloxone for Opiate Dependence in Primary Care
Roy‐Byrne, P. (2006) · Journal watch · doi:10.1056/jp200608070000003
ExtendedvsShort-termBuprenorphine-Naloxone for Treatment of Opioid-Addicted Youth
WOODY, G. E., Poole, S. A., Subramaniam, G., Dugosh, K. L., Bogenschutz, M. P., Abbott, P. J., Patkar, A. A., Publicker, M., McCain, K., Potter, J. S., et al. (2010) · F1000Research · doi:10.7490/f1000research.607.1
Buprenorphine for Opioid Dependence Is Feasible in Primary Care
Saitz, R., FACP., F., & Fasam (2006) · Journal watch · doi:10.1056/jw200608150000001
Mise à jour sur l’utilisation clinique de la buprénorphine
Ducharme, S., Fraser, R., & Gill, K. (2012) · Canadian Family Physician · Cited by 1
Acute Pain Management for Patients on Medication-Assisted Treatment for Opioid-Use Disorder
Mayerson, E. A., & Julian, T. (2017) · Topics in Pain Management · doi:10.1097/01.tpm.0000525815.84692.62
Tierney, M., Melino, K., Adeniji, A., Shumway, M., Allen, I. E., & Waters, C. M. (2018) · Journal of the American Psychiatric Nurses Association · doi:10.1177/1078390318805562
State-of-The-Art Treatment of Opioid Use Disorder
Mooney, L. J., & Saxon, A. J. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-54856-4.00006-7 · Cited by 3
Sanger, K. (2019) · Scholarworks (University of Massachusetts Amherst) · doi:10.7275/13277964 · Cited by 1
Prescribing, Prescription Monitoring, and Health Policy
Gordon, A. J., Cochran, G., Smid, M. C., Manhapra, A., & Kertesz, S. G. (2019) · Current clinical psychiatry · doi:10.1007/978-3-030-16257-3_11
Pineo, C. (2007) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/dbtd-c452
Julian, T. (2019) · Topics in Pain Management · doi:10.1097/01.tpm.0000617884.40854.7f
Principles of Integrating Opioid Use Disorder Treatment in Primary Care
Lu, T. Y., & Cunningham, C. O. (2021) · Springer eBooks · doi:10.1007/978-3-030-80818-1_3
Ville, M. S., Bergen, A. W., Baurley, J. W., Bible, J., & McMahan, C. S. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19095456 · Cited by 1
“It has been shown that illicit opioid use and the number of weeks abstinent from illicit opioid use are significantly associated with daily buprenorphine adherence [5].”
BackgroundFoll, B. L. (2018) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.725450642.793553870
Response to Routsolias and Mycyk Letter
(2021) · Journal of Emergency Nursing · doi:10.1016/j.jen.2021.03.012
Medications for Opioid Use Disorder Do Help Patients.
Nguyen, K.-L., Forbriger, J., Forbriger, A., & Schwarz, E. S. (2022) · PubMed Central
Petropoulos, A. (2023) · Carleton University's Institutional Repository (MacOdrum Library, Carleton University) · doi:10.22215/etd/2023-15433
Long-Term Treatment of Opioid Use Disorder with Medications
Wolfgang, A. S., Weimer, M. B., Na, P. J., Fiellin, D. A., & Muvvala, S. B. (2023) · Oxford University Press eBooks · doi:10.1093/oxfordhb/9780197618431.013.23
Self-citationDisorders Due to Substance Use: Opioids and Opioid Addiction
WOODY, G. E., Kampman, K. M., & Auriacombe, M. (2023) · Springer eBooks · doi:10.1007/978-3-030-42825-9_12-1
Das, S., Chatterjee, S., Mukherjee, A., & Sah, D. (2024) · Personalized Medicine in Psychiatry · doi:10.1016/j.pmip.2024.100120 · Cited by 1
Disorders due to Substance Use: Opioids and Opioid Addiction
WOODY, G. E., Kampman, K. M., & Auriacombe, M. (2024) · Springer eBooks · doi:10.1007/978-3-030-51366-5_12
Derefinko, K. J., Thomas, F., Peter, S. C., Murphy, J. G., Witkiewitz, K. A., Cowan, R. L., Harris, M., Hand, S. B., & Johnson, K. (2025) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2025.112584 · Cited by 1
Beaulieu, É., & Rittenhouse, B. (2025) · Health Services and Outcomes Research Methodology · doi:10.1007/s10742-025-00349-6
Thakrar, A. P., & Rastegar, D. A. (2025) · Oxford University Press eBooks · doi:10.1093/med/9780197796207.003.0006
Strategies for Diagnosis and Management of Opioid Usage Disorder
Nguyen, A., Shah, S., Embry, N. J., Shekoohi, S., & Kaye, A. D. (2025) · Springer eBooks · doi:10.1007/978-3-032-07407-2_16
Saunders, E. C., Moore, S. K., Walsh, O., Metcalf, S. A., Budney, A. J., Cavazos-Rehg, P., Scherer, E. A., & Marsch, L. A. (2021) · Figshare · doi:10.6084/m9.figshare.13647170
Saunders, E. C., Moore, S. K., Walsh, O., Metcalf, S. A., Budney, A. J., Cavazos-Rehg, P., Scherer, E. A., & Marsch, L. A. (2021) · Figshare · doi:10.6084/m9.figshare.13647173
Peter, S. C., Murphy, J. G., Witkiewitz, K. A., Hand, S. B., Thomas, F., Johnson, K. C., Cowan, R. L., Harris, M., & Derefinko, K. J. (2024) · Figshare · doi:10.6084/m9.figshare.26579036
Mammen, A. A., & Thomas, A. A. (2026) · Springer eBooks · doi:10.1007/978-3-031-57159-6_69-1
Cheng, A., Weinstein, Z., Davoust, M. J., Ventura, A. S., Magane, K. M., Theisen, J., Blakemore, S., Saitz, R., & Bazzi, A. R. (2026) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000001702
Lent, M. R., Hurstak, E., Lynch, K. G., Loscalzo, E., Mazur, K., Lugo, H. L., & Dugosh, K. L. (2026) · JAMA Network Open · doi:10.1001/jamanetworkopen.2026.19826
Wenzel, K. R., Schmidt, E., Clinton, C., Guo, K., Pattanaik, S., Thomas, J., Woods, E., Zhang, A., & Fishman, M. J. (2026) · Journal of Substance Use and Addiction Treatment · doi:10.1016/j.josat.2026.210115
Modeling Opioid Addiction Treatment Policies Using System Dynamics
Wakeland, W. W., & Nielsen, A. E. (2013) · PDXScholar (Portland State University)
Metadata
- Authors
- Fiellin, D. A., Pantalon, M. V., Chawarski, M. C., Moore, B. A., Sullivan, L. E., O'Connor, P. G., & Schottenfeld, R. S.
- Affiliations
- Yale University (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2006-07-27
- Volume
- 355
- Issue
- 4
- Pages
- 365-374
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1964032526
- Cited by
- 351
- References
- 30
- Citations by year
- 2026: 5 · 2025: 9 · 2024: 17 · 2023: 14 · 2022: 13 · 2021: 28 · 2020: 18 · 2019: 24 · 2018: 22 · 2017: 19 · 2016: 11 · 2015: 19 · 2014: 18 · 2013: 18 · 2012: 15
- FWCI
- 18.72
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute on Drug Abuse (K24DA000445, K23 DA15144, R01DA009803, K12 DA00167, K23DA015144, K12DA000167)
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Health Sciences › Medicine › Anesthesiology and Pain Medicine › Pain Management and Opioid Use
- Keywords
- opioid use disorder, buprenorphine/naloxone, medication-assisted treatment, counseling, primary care, medication adherence, opioid abstinence, urine drug testing, treatment retention
- MeSH terms
- Adult, Buprenorphine, Combined Modality Therapy, Counseling, Female, Humans, Male, Naloxone, Narcotic Antagonists, Opioid-Related Disorders, Cocaine-Related Disorders
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.